natgillin/translations-raw huggingface dataset:
Certain embodiments provide a compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides and has a nucleobase sequence comprising at least 12 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 6-808. 
Spoj koji sadrži modificirani oligonukleotid i konjugiranu skupinu, gdje modificirani oligonukleotid se sastoji od 20 do 30 vezanih nukleozida i ima nukleobaznu sekvencu SEQ ID NO: 440, gdje je oligonukleotid bar 80% komplementaran sa SEQ ID NO: 1 ili 2 i gdje konjugirana skupina obuhvaća:
The process according to claim 5, characterized in that the ground material is screened and/or concentrated (step e). 
Postupak u skladu s patentnim zahtjevom 3, karakteriziran na način da je usitnjeni materijal prosijan i/ili koncentriran (korak e).
This divider is formed by the series of two equal resistors 76, 77, to the common node of which a terminal of resistor 76 is connected. 
Ovaj djelitelj je sastavljen od dva jednaka otpornika 76, 77 spojenih u seriju, na zajedničku točku na koju je spojen priključak otpornika 76.
The pharmaceutical composition of claim 7, further comprising at least one other anti-cancer therapy optionally selected from radiotherapy, cytotoxic agents, targeted agents, or adjunctive agents. The pharmaceutical composition according to claim 7 or 8 for use in a method of treating cancer in a mammal or for use in treating a protein kinase related disorder in a mammal, the method comprising administering to the mammal in need thereof a therapeutically effective amount of the pharmaceutical composition, optionally wherein the pharmaceutical composition inhibits CSCPKs. 
Farmaceutski sastav iz patentnog zahtjeva 4, nadalje obuhvaća najmanje jedan različiti terapijski agens protiv raka. Farmaceutski sastav iz patentnog zahtjeva 6, pri čemu je navedeni terapijski agens protiv raka najmanje jedan agens odabran iz grupe koja se sastoji od agenasa za radioterapiju (XRT), citotoksičnih agenasa, ciljanih agenasa i adjunktivnih agenasa. Farmaceutski sastav iz patentnog zahtjeva 6 ili 7, pri čemu je navedeni terapijski agens protiv raka odabran iz grupe koja se sastoji gemcitabina, erlotiniba, paklitaksela, docetaksel karboplatine, cisplatine, 5-fluorouracila, doksorubicina, sorafeniba, imatiniba, bevacizumaba, cetuksimaba i trastuzamaba.
To the residue is added dry MeOH (10 mL) and the solution is cooled in an ice bath. 
K ostatku se doda suhi MeOH (10 ml) i otopinu se ohladi u ledenoj kupelji.
The orthopedic screw of any preceding claim, further comprising at least one facet formed in the at least one groove. 
Ortopedski vijak (700) u skladu s patentnim zahtjevom 6, naznačen time što ima: medikamentoznu oblogu, koja se nalazi u u najmanju ruku dijelu najmanje jednog žlijeba.
The mobile station device (50) according to claim 1 or 2, wherein the mobile station device (50) is further adapted to, in the uplink synchronous status, not perform uplink timing alignment based on the timing deviation information included in the random access response (S02). 
Uređaj mobilne stanice (50) prema zahtjevu 1 ili 2, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena koja je uključena u primljenom odgovoru slučajnog pristupa (S02).
the amino acid sequence of positions 118 to 260 (EU numbering) is the sequence described in SEQ ID NO: 24; or the amino acid sequence at positions 261 to 447 (EU numbering) is the sequence described in SEQ ID NO: 26. 
Polipeptidni kompleks u skladu s patentnim zahtjevom 1, naznačen time što Fc domena sadrži bilo koju od niže navedenih aminokiselina, gdje: aminokiselinski slijed na položajima 118 do 260 (EU obrojčavanje) je slijed opisan u SEQ ID NO: 24; ili aminokiselinski slijed na položajima 261 do 447 (EU obrojčavanje) je slijed opisan u SEQ ID NO: 26.
has the sequence of SEQ ID NO: 3; or has at least 99% identity to the sequence of SEQ ID NO: 3 and is a hybrid capsid comprising regions of the AAV3B and AAV8 capsids. 
(i) ima sekvencu SEQ ID NO: 3; ili (1i) ima identitet najmanje 99 %-tno jednak sekvenci SEQ ID NO: 3 i jeste hibridni kapsid koji sadrži regije kapsida AAV3B i AAVS.
Preferred transdermal delivery systems used in accordance with the methods of the present invention include an adhesive layer to affix the dosage form to the skin of the patient for the desired period of administration. 
Preferirani transdermalni sustavi za izdavanje korišteni u skladu s metodama ovog izuma uključuju ljepljivi sloj koji služi pričvršćivanju doze na kožu pacijenta u željenom periodu davanja.
The roll of the preceding claim, wherein the open eutectic carbide network delimits a cell-like pattern of eutectic cells 
Valjak prema prethodnim zahtjevima, pri čemu otvorena eutektična karbidna mreža graniči s stanicama sličnim uzorkom eutektičnih stanica.
Letermovir according to embodiment 6, wherein the process according to step b2) has a final drying step. 
Letermovir prema zahtjevu 1, pri čemu spomenuti postupak ima naknadni korak sušenja in vacuo.
A solution of 4-bromomethyl-biphenyl (Intermediate 1, 3.00 g, 12.2 mmol) in tetrahydrofuran (6 mL) was added dropwise over 10 minutes and the resulting solution stirred at 0° C. for 1.5 hours. 6 M Hydrochloric acid (15 mL) was added; then the crude reaction mixture was extracted with diethyl ether (3×50 mL). 
Otopinu 4-brommetilbifenila (Vleđuprodukt 1, 3,00 g, 12,2 mmol) u tetrahidrofuranu (6 ml) ukapava se 10 minuta, a dobivenu otopinu miješa 1,5 sati na 0 *C. Doda se 6 M klorovodična kiselina (15 ml), a sirovu reakcijsku smjesu ekstrahira dietileterom (3 X 50 ml).
the polyolefin comprises polyethylene or polypropylene. 
(b) poliolefin sadržava polietilen ili polipropilen.
The antibody or a functional fragment of the antibody according to (14), characterized in that the antibody is an antibody produced by hybridoma #32A1 (FERM BP-10999). 
Monoklonsko antitijelo ili njegov funkcionalni fragment, sukladno sa bilo kojim od zahtjeva 1-7, karakteriziranih time da je antitijelo antitijelo proizvedeno od hibridoma stanica FERM BP-10999 (#32A1) ili hibridoma stanica
The composition of any of embodiments 1-14, wherein the biotype has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1. 
Sastav za upotrebu prema bilo kojem od zahtjeva 1-4, pri čemu bakterija ima 16s rRNK sekvencu koja je najmanje 99%, 99.5% ili 99.9% identična sa SEQ ID NO:1.
The composition according to claims 1-3, wherein said sucrose esters or sucresters E473 are in an amount comprised from 10 to 30%, preferably from 15 to 25% by weight. 
estera saharoze ili saharoestera E473, u količini koja se kreće od 10 do 30 %, težinski; i
wherein R1 in each occurrence is independently selected from H, halogen, amino, C1-5 alkyl, C2-5 alkenyl and C2-5 alkynyl; R2 in each occurrence is independently selected from H, halogen, amino, C1-5 alkyl, C2-5 alkenyl and C2-5 alkynyl; and R4 is C1-5 alkyl; the method comprising the step of reacting a compound of formula (III) with a 2-ethylhexanoate salt: 
R' je u svakom slučaju neovisno odabran od H, halogena, amino, C,.5 alkila, C25 alkenila 1 C2 5 alkinila; R? jeu svakom slučaju neovisno odabran od H, halogena, amino, C1.5 alkila, C2_5 alkenila 1 C2.5 alkinila; postupak sadrži korak reakcije spoja formule (III) sa spojem 2-etilhekanoatna sol: m
The compound for use according to claim 6 or 7, wherein the inflammatory condition is rheumatoid arthritis. 
Sol spoja za uporabu prema patentnom zahtjevu 5, pri čemu je upalno stanje reumatoidni artritis.
The self-vector for the use of claim 3 or claim 4, wherein the pharmaceutically acceptable carrier comprises an adjuvant. 
5. = Auto-vektor za uporabu prema zahtjevu 3 ili zahtjevu 4, naznačen time, da farmaceutski prihvatljiv nosač sadrži adjuvant.
In some embodiments, the invention is directed to a pharmaceutical composition comprising an effective amount of the compound SCH 2046273, or a pharmaceutically acceptable isomer, salt or hydrate thereof, and a pharmaceutically acceptable carrier. 
Farmaceutska smjesa koja sadrži učinkovitu količinu spoja, ili njegove farmaceutski prihvatljive soli ili hidrata, prema bilo kojem od prethodnih zahtjeva, i farmaceutski prihvatljivi nosač.
A human SAP polypeptide comprising an N-linked oligosaccharide chain, wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety prepared by a process comprising: 
Humani SAP polipeptid koji sadržava oligosaharidni lanac vezan na N, naznačen time, da najmanje jedan ogranak oligosaharlda završava skupinom sijalične kiseline vezanom na a2,3 koji je pripravljen postupkom koji obuhvaća:
Preferably the MMVF substrate comprises 0.5 to 6 wt% binder, such as 1 to 5 wt% binder, preferably 2 to 4 wt% binder. 
MMYVF supstrat sukladno zahtjevu 16, naznačen time, što MMVF supstrat sadrži 0,5 do 6 tež% veziva.
The composition for the use according to any one of claims 1 to 2, wherein the anti-RSV immune response inducing composition administered to said female was administered during the second or third trimester of pregnancy. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što se pripravak koji izaziva imunosni odgovor protiv RSV kojeg se primjenjuje na navedenoj ženi primjenjuje tijekom drugog ili trećeg tromjesečja trudnoće.
aryl is a homocycle selected from phenyl, naphthyl, acenaphthyl or tetrahydronaphthyl, each being optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl or mono- or dialkylaminocarbonyl. 
erntil aril je homocikal odabran od fenila, naftila, acenaftila ili tetrahidronaftila, koji su svaki proizvoljno supstituirani sa 1, 2 1li 3 substituents, od kojih je svaki supstituent proizvoljno odabran od hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, haloalkila, alkiloksi, haloalkiloksi, karboksila, alkiloksikarbonila, aminokarbonila, morfolinila ili mono- ili dialkilaminokarbonila.
According to another embodiment of the present process, the process further comprises step g) of treating the at least one calcium carbonate-comprising material obtained in step d) or f) with at least one hydrophobizing agent, preferably an aliphatic carboxylic acid having a total amount of carbon atoms from C4 to C24 and/or at least one mono-substituted succinic anhydride consisting of succinic anhydride mono-substituted with a group selected from a linear, branched, aliphatic and cyclic group having a total amount of carbon atoms from C2 to C30 in the substituent and/or a phosphoric acid ester blend of one or more phosphoric acid mono-ester and one or more phosphoric di-ester, to obtain an aqueous suspension comprising a calcium carbonate comprising material comprising on at least a part of the accessible surface area a treatment layer comprising the hydrophobizing agent. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što postupak dodatno uključuje korak g) obrade najmanje jednog materijala koji sadrži kalcijev karbonat dobivenog u koraku d) ili f) najmanje jednim hidrofobizirajućim sredstvom, po mogućnosti alifatskom karboksilnom kiselinom s ukupnom količinom atoma ugljika od C4 do C24 i/ili najmanje jednim monosupstituiranim sukcinanhidridom, koji se sastoji od HR P20190885 T1 sukcinanhidrida monosupstituiranog skupinom koju se bira između nerazgranate, razgranate, alifatske i cikličke skupine s ukupnom količinom atoma ugljika od C2 do C30 u supstituentu i/ili smjese estera fosforne kiseline od jednog ili više monoestera fosforne kiseline i jednog ili više diestera fosforne kiseline, kako bi se dobilo vodenu suspenziju koja sadrži materijal koji sadrži kalcijev karbonat, koji u najmanju ruku ima dio dostupne površine obrađivanog sloja koji sadrži hidrofobizirajuće sredstvo.
The particulate ammonium nitrate-based fertilizer according to claim 16, wherein the particulate ammonium nitrate-based fertilizer is selected from the group consisting of ammonium nitrate fertilizer, calcium ammonium nitrate fertilizer, NPK fertilizer, NP fertilizer and NK fertilizer. 
Praškasto umjetno gnojivo na bazi amonijeva nitrata u skladu s patentnim zahtjevom 16, naznačeno time, da su praškasta umjetna gnojiva na bazi amonijeva nitrata odabrana iz skupine gnojiva amonijeva nitrata, gnojiva kalcijevog amonijeva nitrata, gnojiva NPK (indiferentno NPK, NP, NK) i visokog INIM PK gnojiva.
Process according to Embodiment 1, characterized in that a gas flow is released from the top of the first reactor section and the top of the second reactor section and the combined gas flow of both reactor sections is sent to a medium-pressure scrubber or a high-pressure scrubber, wherein ammonia and carbon dioxide present in the combined gas flow are removed from the gas flow by absorption in a low-pressure carbamate stream. 
Postupak prema zahtjevu 1, naznačen time što se protok plina oslobađa od vrha prvaog reaktorskog dijela i od vrha drugog reaktorskog dijela, a kombinirani protok plina oba odjeljka reaktora šalje sredstvima za gašenje srednjeg tlaka ili sredstvima za gašenje visokog tlaka, pri čemu se amonijak i ugljični dioksid prisutni u kombiniranom protoku plina uklanjaju iz protoka plina apsorpcijom u struji karbamata niskog tlaka.
The solution was preincubated 30 min at 37 °C before use. 
Otopina se ponovno inkubira kroz 30 minuta na 37 "C prije upotrebe.
The method of claim 1, wherein the first program is a host program and the second program is a guest program, the guest program having access to shared resources of the computing environment during a timeslice provided to a guest central processing unit on which the guest program executes, the grace period being distinguishable from the timeslice. 
Računalni sustav u skladu s patentnim zahtjevom 1, naznačen time što gostujući operativni sustav ima pristup dijeljenim resursima računalnog okoliša u odsječku vremena osiguranom za gostujući središnji procesor na kojem gostujući operativni sustav izvršava, gdje se razdoblje počeka razlikuje od odsječka vremena.
A method for treating a disorder associated with CRM1 activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1, wherein the disorder is selected from lupus, multiple sclerosis and amyotrophic lateral sclerosis. 
Spoj za uporabu ili sastav za uporabu prema zahtjevu 8, pri čemu je poremećaj odabran od lupusa, multiple skleroze i amiotrofične lateralne skleroze. Spoj za uporabu ili sastav za uporabu prema zahtjevu 8 ili 9, pri čemu poremećaj je lupus.
The immunogenic composition of claim 1 comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to form N. meningitidis conjugates, wherein each N. meningitidis polysaccharide is either a native polysaccharide or is sized by a factor of no more than x10. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis kojeg se dobiva iz soja kojeg se bira iz skupine koju čine seroskupine A, B, C, W135 i Y.
The system of claim 1, wherein 
Sustav prema zahtjevu 1, gdje
A process according to claim 13, wherein the reducing agent is added with the addition of a base or a basic buffer at a pH of more than 5. 
Postupak prema zahtjevu 13, naznačen time da se redukcijsko sredstvo dodaje uz dodatak baze ili bazičnog pufera kod pH od više od 5.
Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of lower alkyl, halogen or CF3; wherein 
Q je izabrani iz grupe koju čini fenil, piridil, tiazolil, tiofenil, pirimidil, svaki izborno supstituiran sa jednom ili dvije grupe nezavisno izabran iz grupe koju čini Cig alkil, halogen i CF3; gdje
The mixture was filtered, the solid was discarded and the solvent was evaporated to dryness to obtain 2,4-dichloro-3-methyl-benzenesulfonyl chloride as a crystalline white solid. 
Smjesa je filtrirana, krutina je odbačena, a otapalo je upareno do suha i dobiven je 2,4-diklor-3-metil-benzensulfonilklorid kao bijela kristalinična krutina.
determining a second force component corresponding to the second flexural loading detected by the second strain gauge sensor as a transverse thrust force, 
određivanje komponente sile (41) koja odgovara opterećenju savijanja otkrivenim s drugim mjernim senzorom naprezanja, kao poprečne sile potiska FQ.
L1, L2, L3, and L4 are amino acid linkers; wherein: is 3 to 12 amino acid residues in length; 
Li, Lo, 13, i L4 su amino kiselinske poveznice; pri čemu: L, je duljine 3 do 12 ostataka amino kiseline;
Lactose monohydrate, microcrystalline cellulose, the active ingredient, the hydroxypropyl methyl cellulose and a portion of the croscarmellose sodium (in accordance with the formula) were screened into a 10 Liter Fielder high-shear blender (any suitable high shear blender could be used) and blended for 5 minutes at 300 rpm with the chopper off. 
Laktoza monohidrat, mikrokristalna celuloza, aktivni sastojak, hidroksipropil metil celuloza i dio kroskarameloza natrija (u skladu s formulom) se prosije u 10-litrenu Fielder miješalicu s visokim smicanjem (može se upotrijebiti bilo koja miješalica s visokim smicanjem) i miješa 5 minuta pri 300 okr/min s isključenim vibratorom.
A conjugate according to claim 12 or 13 wherein said cell binding agent is chosen from antibodies, fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules. 
Konjugat u skladu s patentnim zahtjevom 3 do 7 naznačen time što se navedeno sredstvo za vezanje na stanicu bira između protutijela ili fragmenta protutijela koji sadrži najmanje jedno vežuće mjesto, limfokina, hormona, čimbenika rasta, molekula za prijenos nutrijenata ili bilo koje druge molekule ili tvari koja se veže na stanicu.
at each occurrence is independently selected from H, F, Cl, Br, C1-C6 alkyl, C1-C6 and alkyloxy; y is 0, 1 or 2 comprising the steps of: 
R* uvijek kada se pojavljuje je neovisno odabran od H, F, Cl, Br, C,-C; alkila, i C,-C; alkiloksi; xje1,2,31li 4; naznačen time da sadrži korake:
g of rifamycin SV are mixed with 5 g of stearic acid, 7 g of carnauba wax, 8 g of sodium dioctyl sulphosuccinate, 100 g of lactose and 10 g of sodium edetate and granulated with a solution containing 25 g of low-viscosity polyvinylpyrrolidone in 0.2 liter of purified water. 
Smjesa 200 g rifamicina SV sa 5 g stearinske kiseline, 7 g karnauba voska, 8 g natrij dioctil sulfosukcinata, 100 g laktoze i 10 g natrij edetata granulirana je otopinom koja sadrži 25 g polivinil pirolidona niske viskoznosti u 0,2 L pročišćene vode.
A method according to claim 4 wherein the psychiatric disorder is bipolar disorder. 
Uporaba prema zahtjevu 4 naznačena time da psihijatrijski poremećaj je bipolarni poremećaj.
The first toothed cylinder 25 of the second screw 24 is therefore engaged in the toothing 22 present in the second seat 21. 
Prvi nazubljeni cilindar 25 drugog vijka 24 se zbog toga zahvati u nazubljenje 22 koje se nalazi u drugom dosjedu 21.
Advantageously, said partially detachable packaging section is completely detachable. Preferably, said incision line on the periphery of said first zone comprises a priming part arranged to facilitate priming of the partially detachable packaging section, for example a more dense incision, an opening or a tab. 
Uzorak ambalažnog pakiranja u skladu sa zahtjevima 12 ili 13, naznačen time da navedena rezna linija na periferiji navedene središnje zone navedene prve zone (3) sadrži početni dio za olakšavanje započinjanja folije, na primjer gušći rez, otvor ili jezičac.
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; treating the compound of formula (5), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, with an aldehyde under suitable conditions to form a compound of formula (6): 
HO S N ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (5), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, aldehidom u uvjetima pogodnim za dobivanje spoja formule (6):
The composition according to Claim 1, wherein the particle D50 of the cinacalcet HCI particles is less than or equal to 50 µm. 
Smjesa prema zahtjevu 8, gdje je Dso čestica sinakalcet HCI manji ili jednak 50 um.
The IR, NMR and MS data for Isomer D are set out in Table 2 and the Chiral HPLC and ORD data are set out in Table 4. 
Podaci IR, NMR 1 MS za Izomer D su prikazani u Tabeli 2 i podaci za hiralnu HPLC i ORD su prikazani u Tabeli 4.
The results are summarized in Table 3. 
Rezultati su prikazani u Tablici 3.
The antibody of any one of claims 1-5 and 11 or the composition of claim 6 for use in blocking or preventing attachment of P. aeruginosa to epithelial cells, wherein a mixture of epithelial cells and P. aeruginosa are contacted with the antibody or the composition. 
Protutijelo prema bilo kojem od zahtjeva 1-5 1 11 ili pripravak prema zahtjevu 6 naznačeno time daje za uporabu za blokiranje 1li sprječavanje spajanja P. aeruginosa na epitelne stanice, pri čemu se smjesa epitelnih stanica 1 P. aeruginosa dovodi u kontakt s protutijelom ili pripravkom.
The phosphate solid form of any of claims 1-13 for use in the treatment of pain in a patient. 
Farmaceutska smjesa iz bilo kojeg od patentnih zahtjeva 10 do 14, naznačena time, što se upotrebljava za liječenje boli kod pacijenta.
A reversible, short-acting P2Y12 inhibitor for use in a method according to any one of the preceding claims, wherein administration of the at least one thienopyridine to the subject is discontinued at least five days prior to an invasive procedure to be performed on the subject. 
Reverzibilni, kratko djelujući inhibitor P2Y;, za uporabu u postupku prema bilo kojem od prethodnih zahtjeva, naznačen time da se davanje barem jednog tienopiridina subjektu prekida barem pet dana prije invazivnog postupka koji se provodi na subjektu.
The anti-CGRP antagonist antibody of any preceding claim, wherein the antibody is: (a) an antibody having a CDR H1 as set forth in SEQ ID NO: 3; a CDR H2 as set forth in SEQ ID NO: 4; a CDR H3 as set forth in SEQ ID NO: 5; a CDR L1 as set forth in SEQ ID NO: 6; a CDR L2 as set forth in SEQ ID NO: 7; and a CDR L3 as set forth in SEQ ID NO: 8; or (b) a variant of an antibody of (a) as shown in Table 6. 
Anti-CGRP antagonističko protutijelo za uporabu prema bilo kojem prethodnom zahtjevu, naznačeno time da je protutijelo: (a) protutijelo koje ima CDR H1 kao što se navodi u SEQ ID NO: 3; CDR H2 kao što se navodi u SEQ ID NO: 4; CDR H3 kao što se navodi u SEQ ID NO: 5; CDR L1 kao što se navodi u SEQ ID NO: 6; CDR L2 kao što se navodi u SEQ ID NO: 7; i CDR L3 kao što se navodi u SEQ ID NO: 8; ili (b) varijantu protutijela pod (a) kao što je prikazano u Tablici 6.
reconstructing an intra prediction mode and creating a prediction block of a current block or a sub block of the current block; 
modul (240) za intrapredikciju konfiguriran da rekonstruira intrapredikcijski režim i da kreira predikcijski blok tekućeg bloka ili podbloka tekućeg bloka;
The composition of claim 1, wherein the carbohydrate is present in an amount sufficient to have stability comparable to that of a lyophilized composition comprising sucrose, 0.01% polysorbate-20, pH 6.0, 50 mM Citrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da ona ima stabilnost koja odgovara onoj za liofiliziranu kompoziciju koja sadrži saharozu, 0,01 % polisorbata-20, pH 6,0, 50 mM citrata.